1
|
Ferulic acid alleviates abnormal behaviors in isolation-reared mice via 5-HT 1A receptor partial agonist activity. Psychopharmacology (Berl) 2021; 238:2147-2154. [PMID: 33829309 DOI: 10.1007/s00213-021-05839-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 03/25/2021] [Indexed: 10/21/2022]
Abstract
RATIONALE Preclinical and clinical reports suggest that ferulic acid (FA), a plant-derived phenylpropanoid, is effective against mental health problems such as agitation, anxiety, and irritability in humans, without causing adverse side effects. However, the mechanism of action is unknown. OBJECTIVE The aim of the study is to investigate the mechanism underlying the ameliorative effects of FA on mental health problems such as agitation, anxiety, and irritability, using in vivo behavioral analysis, in vitro pharmacological analysis, and in silico binding analysis. METHODS The effects of FA (10 mg/kg, 50 mg/kg, and 250 mg/kg) on hyperactivity and aggressive behaviors of isolation-reared mice were examined. The effects of FA (50 mg/kg and 250 mg/kg) on extracellular levels of monoamines such as serotonin (5-HT), dopamine, and noradrenaline were analyzed by in vivo microdialysis. The effects of FA (10-13-10-6 M) on 5-HT1A and 5-HT2A receptors were analyzed using a luciferase reporter gene assay. Binding of FA to the mouse 5-HT1A receptor was evaluated by in silico analysis. RESULTS The behavioral analysis showed that administration of FA (50 mg/kg) 1 h before experiments significantly alleviated hyperactivity and aggressive behaviors in isolation-reared mice. These alleviative effects were abolished by pretreatment with the 5-HT1A receptor antagonist WAY-100635 (1 mg/kg). In vivo microdialysis analysis showed that FA (50 mg/kg) did not change extracellular monoamine levels in the prefrontal cortex of mice. The luciferase reporter gene assay indicated that FA activated 5-HT1A receptors, but not 5-HT2A receptors, in a dose-dependent manner. The maximal response of 5-HT1A receptors to FA was weaker than that to 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT), a 5-HT1A receptor full agonist. In silico binding analysis showed that FA binds to the orthosteric site of 5-HT1A receptors. CONCLUSION Taken together, these results suggest that FA ameliorates agitation-, anxiety-, and irritability-like behaviors such as hyperactivity and aggressive behaviors in isolation-reared mice via 5-HT1A receptor partial agonist activity. These findings support the efficacy of FA on mental health problems that have been suggested in preclinical and clinical practice.
Collapse
|
2
|
Kim S, Lee DW, Schachner M, Park HC. Small compounds mimicking the adhesion molecule L1 improve recovery in a zebrafish demyelination model. Sci Rep 2021; 11:5878. [PMID: 33723325 PMCID: PMC7960995 DOI: 10.1038/s41598-021-85412-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Accepted: 03/01/2021] [Indexed: 02/05/2023] Open
Abstract
Demyelination leads to a loss of neurons, which results in, among other consequences, a severe reduction in locomotor function, and underlies several diseases in humans including multiple sclerosis and polyneuropathies. Considerable clinical progress has been made in counteracting demyelination. However, there remains a need for novel methods that reduce demyelination while concomitantly achieving remyelination, thus complementing the currently available tools to ameliorate demyelinating diseases. In this study, we used an established zebrafish demyelination model to test selected compounds, following a screening in cell culture experiments and in a mouse model of spinal cord injury that was aimed at identifying beneficial functions of the neural cell adhesion molecule L1. In comparison to mammalian nervous system disease models, the zebrafish allows testing of potentially promotive compounds more easily than what is possible in mammals. We found that our selected compounds tacrine and duloxetine significantly improved remyelination in the peripheral and central nervous system of transgenic zebrafish following pharmacologically induced demyelination. Given that both molecules are known to positively affect functions other than those related to L1 and in other disease contexts, we propose that their combined beneficial function raises hope for the use of these compounds in clinical settings.
Collapse
Affiliation(s)
- Suhyun Kim
- Department of Biomedical Sciences, College of Medicine, Korea University, Ansan, 15335, Republic of Korea
| | - Dong-Won Lee
- Department of Biomedical Sciences, College of Medicine, Korea University, Ansan, 15335, Republic of Korea
| | - Melitta Schachner
- Keck Center for Collaborative Neuroscience and Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, 08554, USA.
- Center for Neuroscience, Shantou University Medical College, Shantou, 515041, Guangdong, China.
| | - Hae-Chul Park
- Department of Biomedical Sciences, College of Medicine, Korea University, Ansan, 15335, Republic of Korea.
| |
Collapse
|
5
|
Hasebe S, Ago Y, Watabe Y, Oka S, Hiramatsu N, Tanaka T, Umehara C, Hashimoto H, Takuma K, Matsuda T. Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice. Br J Pharmacol 2017; 174:314-327. [PMID: 27987210 PMCID: PMC5289945 DOI: 10.1111/bph.13692] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Revised: 12/07/2016] [Accepted: 12/09/2016] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE Prefrontal dopamine release by the combined activation of 5-HT1A and sigma-1 (σ1 ) receptors is enhanced by the GABAA receptor antagonist picrotoxin in mice. Here, we examined whether this neurochemical event was accompanied by behavioural changes. EXPERIMENTAL APPROACH Male mice were treated with picrotoxin to decrease GABAA receptor function. Their anhedonic behaviour was measured using the female encounter test. The expression of c-Fos was determined immunohistochemically. KEY RESULTS Picrotoxin caused an anxiogenic effect on three behavioural tests, but it did not affect the immobility time in the forced swim test. Picrotoxin decreased female preference in the female encounter test and attenuated the female encounter-induced increase in c-Fos expression in the nucleus accumbens. Picrotoxin-induced anhedonia was ameliorated by fluvoxamine and S-(+)-fluoxetine, selective serotonin reuptake inhibitors with high affinity for the σ1 receptor. The effect of fluvoxamine was blocked by a 5-HT1A or a σ1 receptor antagonist, and co-administration of the σ1 receptor agonist (+)-SKF-10047 and the 5-HT1A receptor agonist osemozotan mimicked the effect of fluvoxamine. By contrast, desipramine, duloxetine and paroxetine, which have little affinity for the σ1 receptor, did not affect picrotoxin-induced anhedonia. The effect of fluvoxamine was blocked by a dopamine D2/3 receptor antagonist. Methylphenidate, an activator of the prefrontal dopamine system, ameliorated picrotoxin-induced anhedonia. CONCLUSION AND IMPLICATIONS Picrotoxin-treated mice show anhedonic behaviour that is ameliorated by simultaneous activation of 5-HT1A and σ1 receptors. These findings suggest that the increased prefrontal dopamine release is associated with the anti-anhedonic effect observed in picrotoxin-treated mice.
Collapse
Affiliation(s)
- S Hasebe
- Department of Pharmacology, Graduate School of DentistryOsaka UniversityOsakaJapan
| | - Y Ago
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| | - Y Watabe
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| | - S Oka
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| | - N Hiramatsu
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| | - T Tanaka
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| | - C Umehara
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| | - H Hashimoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
- United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of FukuiOsakaJapan
- Division of Bioscience, Institute for Datability ScienceOsaka UniversityOsakaJapan
| | - K Takuma
- Department of Pharmacology, Graduate School of DentistryOsaka UniversityOsakaJapan
- United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of FukuiOsakaJapan
| | - T Matsuda
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical SciencesOsaka UniversityOsakaJapan
| |
Collapse
|
6
|
Tanaka T, Ago Y, Umehara C, Imoto E, Hasebe S, Hashimoto H, Takuma K, Matsuda T. Role of Prefrontal Serotonergic and Dopaminergic Systems in Encounter-Induced Hyperactivity in Methamphetamine-Sensitized Mice. Int J Neuropsychopharmacol 2016; 20:410-421. [PMID: 28034961 PMCID: PMC5417057 DOI: 10.1093/ijnp/pyw115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 12/20/2016] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Isolation-reared mice show social encounter-induced hyperactivity with activation of prefrontal serotonergic and dopaminergic systems, but it is not known whether this stress response is observed in other pathological conditions. Here we examined whether the social encounter stimulation induces abnormal behavior during withdrawal in chronic methamphetamine-treated mice. METHODS To induce methamphetamine-induced behavioral sensitization, male mice were injected with methamphetamine (1 mg/kg) once daily for 7 days. RESULTS The encounter with an intruder elicited hyperactivity 24 h after the last injection of methamphetamine in methamphetamine-sensitized mice. This response was observed even as long as 2 weeks after withdrawal of methamphetamine. The encounter increased c-Fos expression in the prefrontal cortex, dorsal raphe nucleus and ventral tegmental area in methamphetamine-sensitized mice, while it did not in control mice. Furthermore, the encounter increased extracellular serotonin (5-HT) and dopamine, but not noradrenaline, levels in the prefrontal cortex in methamphetamine-sensitized mice. Local injection of 5,7-dihydroxytryptamine and 6-hydroxydopamine into the prefrontal cortex attenuated encounter-induced hyperactivity in methamphetamine-sensitized mice and it markedly decreased prefrontal 5-HT and dopamine levels, respectively. Pharmacological analysis showed that the encounter-induced hyperactivity is mediated by dopamine D1 receptors and 5-HT2A receptors and attenuated by anxiolytics and antidepressants such as diazepam, osemozotan and selective 5-HT reuptake inhibitors. The effect of paroxetine was blocked by the 5-HT3 receptor antagonist azasetron. CONCLUSIONS The present study shows that psychological stress elicits hyperactivity with activation of prefrontal 5-HT and dopamine systems in methamphetamine-dependent mice and suggests that the abnormal behavior is associated with anxiety and depression.
Collapse
Affiliation(s)
- Tatsunori Tanaka
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Yukio Ago
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Chiaki Umehara
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Emina Imoto
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Shigeru Hasebe
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Hitoshi Hashimoto
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Kazuhiro Takuma
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| | - Toshio Matsuda
- Laboratory of Molecular Neuropharmacology (Mr Tanaka, Dr Ago, Ms Umehara, and Dr Hashimoto), and Department of Pharmacology, Graduate School of Dentistry, Osaka University, Osaka, Japan (Mr Hasebe and Dr Takuma); United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, Japan (Drs Hashimoto and Takuma); Division of Bioscience, Institute for Datability Science (Dr Hashimoto), and Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences (Ms Imoto and Dr Matsuda), Osaka University, Osaka, Japan
| |
Collapse
|
9
|
Hara Y, Ago Y, Taruta A, Katashiba K, Hasebe S, Takano E, Onaka Y, Hashimoto H, Matsuda T, Takuma K. Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism. Autism Res 2015; 9:926-39. [DOI: 10.1002/aur.1596] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Accepted: 12/03/2015] [Indexed: 12/30/2022]
Affiliation(s)
- Yuta Hara
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University; Suita Osaka Japan
| | - Yukio Ago
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University; Suita Osaka Japan
| | - Atsuki Taruta
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University; Suita Osaka Japan
| | - Keisuke Katashiba
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University; Suita Osaka Japan
| | - Shigeru Hasebe
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
- Department of Pharmacology; Graduate School of Dentistry, Osaka University; Suita Osaka Japan
| | - Erika Takano
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
| | - Yusuke Onaka
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University; Suita Osaka Japan
| | - Hitoshi Hashimoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University; Suita Osaka Japan
- United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui; Suita Osaka Japan
| | - Toshio Matsuda
- Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences; Osaka University; Suita Osaka Japan
| | - Kazuhiro Takuma
- Department of Pharmacology; Graduate School of Dentistry, Osaka University; Suita Osaka Japan
- United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui; Suita Osaka Japan
| |
Collapse
|